{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:18:01Z","timestamp":1776176281848,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd010117","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T00:00:00Z","timestamp":1640476800000}}],"reference-count":58,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010117.pub2","type":"journal-article","created":{"date-parts":[[2021,12,26]],"date-time":"2021-12-26T19:22:38Z","timestamp":1640546558000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Propionyl-L-carnitine for intermittent claudication"],"prefix":"10.1002","volume":"2021","author":[{"given":"Victor","family":"Kamoen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences; Ghent University; Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Vander Stichele","sequence":"additional","affiliation":[{"name":"Heymans Institute of Pharmacology; Ghent University; Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Campens","sequence":"additional","affiliation":[{"name":"Center for Medical Genetics; Ghent University Hospital; Ghent Belgium"},{"name":"Cardiovascular Center; Ghent University Hospital; Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"De Bacquer","sequence":"additional","affiliation":[{"name":"Department of Public Health; Ghent University; Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Van Bortel","sequence":"additional","affiliation":[{"name":"Heymans Institute of Pharmacology; Ghent University; Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tine LM","family":"de Backer","sequence":"additional","affiliation":[{"name":"Heymans Institute of Pharmacology; Ghent University; Ghent Belgium"},{"name":"Cardiovascular Center; Ghent University Hospital; Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,26]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD010117.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/0003319707304567","article-title":"Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication","volume":"59","author":"Andreozzi","year":"2008","journal-title":"Angiology"},{"issue":"2","key":"10.1002\/14651858.CD010117.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.eurheartj.a060155","article-title":"Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study","volume":"13","author":"Brevetti","year":"1992","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD010117.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/0735-1097(95)00344-4","article-title":"Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study","volume":"26","author":"Brevetti","year":"1995","journal-title":"Journal of American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD010117.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0002-9149(96)00867-3","article-title":"Effect of propionyl-L-carnitine on quality of life in intermittent claudication","volume":"79","author":"Brevetti","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD010117.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0735-1097(99)00373-3","article-title":"European multicenter study on propionyl-l-carnitine in intermittent claudication","volume":"34","author":"Brevetti","year":"1999","journal-title":"Journal of American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD010117.pub2-BIB0006|cit6","first-page":"29","article-title":"Evaluation of the therapeutic efficacy and tolerability of levocarnitine propionyl in the treatment of chronic obstructive arteriopathies of the lower extremities: a multicentre controlled study vs. placebo","volume":"18","author":"Coto","year":"1992","journal-title":"Drugs under Experimental and Clinical Research"},{"issue":"1","key":"10.1002\/14651858.CD010117.pub2-BIB0007|cit7","first-page":"29","article-title":"Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial","volume":"25","author":"Dal Lago","year":"1999","journal-title":"Drugs under Experimental and Clinical Research"},{"issue":"2","key":"10.1002\/14651858.CD010117.pub2-BIB0008|cit8","first-page":"69","article-title":"Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: controlled double-blind trial versus placebo","volume":"18","author":"Greco","year":"1992","journal-title":"Drugs under Experimental and Clinical Research"},{"issue":"8","key":"10.1002\/14651858.CD010117.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0002-9343(01)00704-5","article-title":"Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication","volume":"110","author":"Hiatt","year":"2001","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010117.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/HCR.0b013e3181f1fd65","article-title":"Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral arterial disease","volume":"31","author":"Hiatt","year":"2011","journal-title":"Journal Cardiopulmonary Rehabilitation Prevention"},{"issue":"4","key":"10.1002\/14651858.CD010117.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.thromres.2013.08.005","article-title":"A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication","volume":"132","author":"Luo","year":"2013","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0012|cit12","unstructured":"A clinical study on efficacy & safety profile of propionyl-L-carnitine tablets for peripheral arterial diseases clinicaltrialsgov\/show\/NCT00809497"},{"issue":"3","key":"10.1002\/14651858.CD010117.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diabres.2005.10.007","article-title":"Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD","volume":"72","author":"Signorelli","year":"2006","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD010117.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002512-200623030-00008","article-title":"A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl-L-carnitine in patients with peripheral arterial disease requiring hemodialysis","volume":"23","author":"Signorelli","year":"2006","journal-title":"Drugs and Aging"},{"issue":"2","key":"10.1002\/14651858.CD010117.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000094363","article-title":"Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease","volume":"29","author":"Signorelli","year":"2006","journal-title":"Kidney & Blood Pressure Research"},{"issue":"4","key":"10.1002\/14651858.CD010117.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.avsg.2008.02.010","article-title":"Propionyl-L-carnitine in Leriche-Fontaine stage II peripheral arterial obstructive disease","volume":"22","author":"Allegra","year":"2008","journal-title":"Annals of Vascular Surgery"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/00005768-200109000-00001","article-title":"Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease","volume":"33","author":"Barker","year":"2001","journal-title":"Medicine and Science in Sports and Exercise"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0018|cit18","first-page":"138","article-title":"L-carnitine increases walking distance in patients with peripheral arterial disease (Abstract)","volume":"5(Suppl 1)","author":"Brevetti","year":"1984","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD010117.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.CIR.77.4.767","article-title":"Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study","volume":"77","author":"Brevetti","year":"1988","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/000331978904001001","article-title":"Effects of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, cross-over study","volume":"40","author":"Brevetti","year":"1989","journal-title":"Angiology"},{"issue":"9","key":"10.1002\/14651858.CD010117.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1161\/01.CIR.93.9.1685","article-title":"Carnitine-related alternations in patients with intermittent claudication: indication for a focused carnitine therapy","volume":"93","author":"Brevetti","year":"1996","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD010117.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1358863X12442264","article-title":"L-carnitine plus cilostazol verus cilostazol alone for the treatment of claudication in patients with peripheral arterial disease: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"17","author":"Goldenberg","year":"2012","journal-title":"Vascular Medicine"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0023|cit23","unstructured":"The effect of carnitine for intermittent claudication of peripheral arterial disease patient with sarcopenia and carnitine deficiency apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000016267"},{"issue":"3","key":"10.1002\/14651858.CD010117.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jvs.2006.05.023","article-title":"Imbalance between nitric oxide generation and oxidative stress in patients with peripheral arterial disease: effect on antioxidant treatment","volume":"44","author":"Loffredo","year":"2006","journal-title":"Journal of Vascular Surgery"},{"issue":"1","key":"10.1002\/14651858.CD010117.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2012.01.069","article-title":"NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease","volume":"165","author":"Loffredo","year":"2013","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD010117.pub2-BIB0026|cit26","first-page":"185","article-title":"Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial","volume":"5","author":"Ragozzino","year":"2004","journal-title":"Drugs in Research and Development"},{"issue":"3","key":"10.1002\/14651858.CD010117.pub2-BIB0027|cit27","first-page":"253","article-title":"Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II","volume":"27","author":"Riccioni","year":"2008","journal-title":"International Angiology"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200222001-00001","article-title":"Propionyl-L-carnitine versus pentoxifylline: improvement in walking capacity in patients with intermittent claudication","volume":"22(Suppl 1)","author":"Strano","year":"2002","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1002\/14651858.CD010117.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/1358863X9600100401","article-title":"Changes in energy metabolism of calf muscle in patients with intermittent claudication assessed by 31P magnetic resonance spectroscopy: a phase II open study","volume":"1","author":"Taylor","year":"1996","journal-title":"Vascular Medicine (London, England)"},{"issue":"16","key":"10.1002\/14651858.CD010117.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1517\/14656560903215871","article-title":"Propionyl-l-carnitine: intermittent claudication and peripheral arterial disease","volume":"10","author":"Andreozzi","year":"2009","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD010117.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/07315724.1998.10718750","article-title":"The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs","volume":"17","author":"Brass","year":"1998","journal-title":"Journal of the American College of Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD010117.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1358863X12467491","article-title":"A systematic review and meta-analysis of propionyl-l-carnitine effects on exercise performance in patients with claudication","volume":"18","author":"Brass","year":"2013","journal-title":"Vascular Medicine"},{"issue":"9","key":"10.1002\/14651858.CD010117.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1115::AID-MUS4>3.0.CO;2-B","article-title":"Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine","volume":"20","author":"Brevetti","year":"1997","journal-title":"Muscle and Nerve"},{"issue":"6","key":"10.1002\/14651858.CD010117.pub2-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003748.pub5","article-title":"Cilostazol for intermittent claudication","author":"Brown","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010117.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/157016110791112278","article-title":"Silence of the limbs: pharmacological symptomatic treatment of intermittent claudication","volume":"8","author":"De Backer","year":"2010","journal-title":"Current Vascular Pharmacology"},{"issue":"12","key":"10.1002\/14651858.CD010117.pub2-BIB0036|cit36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001368.pub4","article-title":"Naftidrofuryl for intermittent claudication","author":"Backer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0037|cit37","unstructured":"Deckert J Propionyl-L-carnitine for intermittent claudication Journal of Family Practice 1997 44 6 533 4"},{"issue":"1","key":"10.1002\/14651858.CD010117.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2013.03.004","article-title":"A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication","volume":"229","author":"Delaney","year":"2013","journal-title":"Atherosclerosis"},{"issue":"7109","key":"10.1002\/14651858.CD010117.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD010117.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2165\/00003088-200342110-00002","article-title":"Pharmacokinetics of L-carnitine","volume":"42","author":"Evans","year":"2003","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0041|cit41","first-page":"499","article-title":"Surgical treatment for peripheral vascular disease","volume":"5\/6","author":"Fontaine","year":"1954","journal-title":"Helvetica Chirurgica Acta"},{"issue":"2","key":"10.1002\/14651858.CD010117.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/ije\/20.2.384","article-title":"Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population","volume":"20","author":"Fowkes","year":"1991","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0043|cit43","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"issue":"7651","key":"10.1002\/14651858.CD010117.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD010117.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"5","key":"10.1002\/14651858.CD010117.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/01.CIR.91.5.1472","article-title":"Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study","volume":"91","author":"Hiatt","year":"1995","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1196\/annals.1320.008","article-title":"Carnitine and peripheral arterial disease","volume":"1033","author":"Hiatt","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"25","key":"10.1002\/14651858.CD010117.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2826-9","DOI":"10.1161\/CIRCULATIONAHA.108.191171","article-title":"Atherosclerotic Peripheral Vascular Disease Symposium II. Nomenclature for vascular diseases","volume":"118","author":"Hiatt","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0049|cit49","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0050|cit50","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6. Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"1","key":"10.1002\/14651858.CD010117.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/028134302317282716","article-title":"Incidence and management of intermittent claudication in primary care in The Netherlands","volume":"20","author":"Meijer","year":"2002","journal-title":"Scandinavian Journal of Primary Health Care"},{"issue":"4","key":"10.1002\/14651858.CD010117.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10557-009-6178-3","article-title":"Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1","volume":"23","author":"Milio","year":"2009","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"5","key":"10.1002\/14651858.CD010117.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00003495-200059050-00003","article-title":"Pharmacological management of intermittent claudication: a meta-analysis of randomized trials","volume":"59","author":"Moher","year":"2000","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"33 (Suppl 1)","author":"Norgren","year":"2007","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0055|cit55","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12. Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"6","key":"10.1002\/14651858.CD010117.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jvs.2007.02.004","article-title":"A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences","volume":"45","author":"Sigvant","year":"2007","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD010117.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1113\/jphysiol.2006.125799","article-title":"New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle","volume":"581(Pt 2)","author":"Stephens","year":"2007","journal-title":"Journal of Physiology"},{"issue":"9","key":"10.1002\/14651858.CD010117.pub2-BIB0058|cit58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010117","article-title":"Propionyl-L-carnitine for intermittent claudication","author":"Backer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:39:53Z","timestamp":1664789993000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010117.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,26]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010117.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,26]]}}}